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Abstract 
Background: Exosomes are endocytic‑extracellular vesicles with a diameter around 100 nm that play an essential 
role on the communication between cells. In fact, they have been proposed as candidates for the diagnosis and the 
monitoring of different pathologies (such as Parkinson, Alzheimer, diabetes, cardiac damage, infection diseases or 
cancer).
Results: In this study, magnetic nanoparticles  (Fe3O4NPs) were successfully functionalized with an exosome‑binding 
antibody (anti‑CD9) to mediate the magnetic capture in a microdevice. This was carried out under flow in a 1.6 mm 
(outer diameter) microchannel whose wall was in contact with a set of NdFeB permanent magnets, giving a high 
magnetic field across the channel diameter that allowed exosome separation with a high yield. To show the useful‑
ness of the method, the direct capture of exosomes from whole blood of patients with pancreatic cancer (PC) was 
performed, as a proof of concept. The captured exosomes were then subjected to analysis of CA19‑9, a protein often 
used to monitor PC patients.
Conclusions: Here, we describe a new microfluidic device and the procedure for the isolation of exosomes from 
whole blood, without any need of previous isolation steps, thereby facilitating translation to the clinic. The results 
show that, for the cases analyzed, the evaluation of CA19‑9 in exosomes was highly sensitive, compared to serum 
samples.
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Background
Exosomes are nano-sized  vesicles with a diameter from 
approximately 30 to 150 nm secreted by a wide range of 
cells including immune, neuronal, cancer and stem cells 
[1, 2]. They are delimited by a cell-type lipidic membrane 
and, depending on their parental cell and tissue of origin, 
they are also enriched in specific cargo of proteins and 
RNAs [3–5]. In fact, some works affirm that the proteome 
and the transcriptome of exosomes mirror their parental 
cells, highlighting the employment of this molecular sig-
nature in exosomes for the treatment and diagnosis of 
different pathologies [6–10].
Bioavailability and accessibility in body fluids (blood, 
semen, breast milk, urine, cerebrospinal fluid and saliva) 
make of exosomes very useful minimally invasive tools for 
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diagnosis and prognostic applications [11–13]. In fact, they 
have been proposed as excellent candidates for the diagnos-
tic and the monitoring of Parkinson, Alzheimer, diabetes, 
cardiac damages, infectious diseases or cancer [14–17].
The most widely employed purification procedure 
for exosome isolation is differential ultracentrifugation. 
This strategy is based on the staged removal of whole 
cells, cellular debris and large organelles based on their 
different sizes and densities [18]. This technique is labo-
rious, time consuming, expensive and in the case of exo-
some isolation from whole blood, the purification yields 
are significantly low, from 5 to 40% [19]. In addition, 
ultracentrifugation requires high volumes of sample, an 
obvious limitation regarding to patient blood samples 
[18]. Although other discontinuous methods have been 
developed in recent years (immunoaffinity capture, com-
mercial kits, nanostructured based filtration, size exclu-
sion chromatography, acoustic platforms or dialysis 
membrane filtration), they frequently suffer from limita-
tions including the necessity of additional reagents, long 
processing time, low reproducibility and low exosome 
purity [20]. On the contrary, microfluidic devices are now 
emerging as novel platforms for exosome isolation [21, 
22]. These technologies have advantages such as specific 
separation with high purity, low cost, size uniformity of 
isolated exosomes and speed of processing compared to 
other methods [21]. Among the microfluidic-based tech-
nologies, the immune affinity approach is the most widely 
used with antibodies grafted on the vesicles surface (e.g., 
CD63, CD9 or CD81) that enable specific recognition 
from other membrane-derived vesicles and lipidic struc-
tures. To date, several microfluidic-based techniques 
have been employed for exosomes analysis [21, 23, 24].
Oncology is perhaps the most promising field of appli-
cation of exosome-based diagnosis. It has been described 
that tumor-exosomes reflect the composition of tumor 
cells, highlighting their potential use in cancer diagno-
sis. Indeed, tumor cells have been described to secrete 
a significantly higher  amount of extracellular vesicles 
(EVs) compared to the levels of healthy cells, for instance 
in metastatic melanoma patients [25]. In fact, Balaj et al. 
[26], observed that one cancer cell could release from 
7000 to 25,000 microvesicles in 48 h whereas a non-path-
ological fibroblast secretes from 3800 to 6200 vesicles 
during the same time. Therefore, exosome levels in body 
fluids from cancer patients (including blood) are signifi-
cantly higher [27]; and the amount of exosomes secreted 
by cancer cells (overexpressing some cancer-derived bio-
markers) is also higher compared to normal cells. Conse-
quently, the isolation of exosomes from body fluids could 
provide us with information on a specific pathological 
condition and gives useful clues about the state or pro-
gress of a specific disease. Recent research has focused on 
circulating exosomes as suitable biomarkers for tumor 
liquid biopsy [28, 29]. Malla et al. [30], showed that the 
differential expression of serum exosomal miRNAs 
before and after radiotherapy can serve as potential indi-
cators of prostate cancer patients’ response to the treat-
ment and prognosis. Furthermore, exosomal proteins are 
differentially expressed in highly metastatic Panc01-H7 
cells versus weakly metastatic Pan01 cells, providing a 
potential way to classify the aggressiveness of the tumors 
[31].
Monitoring exosomes also seems to be advantageous 
versus the monitoring of circulating tumor cells (CTC), 
since the concentration of exosomes from tumor cells in 
blood is much higher than the amount of CTCs (1–10 
circulating CTC/mL against ≥ 109 vesicles/mL in blood). 
This abundance could allow the detection and diagnosis 
of early stage tumors, before a metastatic phase develops 
[24, 32, 33].
In summary tumor-associated exosomes present sig-
nificant advantages as potential diagnosis tools for can-
cer including: (1) their content is related to the cell type 
of origin. Therefore, specific proteins or RNAs are often 
enriched in these vesicles, (2) exosome content is pro-
tected by the lipidic membrane of the vesicles, (3) they 
are very stable and can be stored for extended periods of 
time, (4) the number of exosomes secreted by cancer cells 
is high, and as a consequence they are abundant in the 
blood of cancer patients.
In this work we have designed a microfluidic separa-
tion device based on magnetic nanoparticles  (Fe3O4NPs) 
functionalized with antibodies. While this separator 
might be applied for isolation of exosomes from several 
patients with different pathologies, we have demon-
strated the functionality of the device in the separation 
of exosomes from patients´ whole blood with pancre-
atic cancer (PC), a condition where early diagnosis is 
particularly important: poor prognosis is frequent due 
to late-phase diagnosis in advanced stages [34]. CA19-9 
protein is currently the only FDA-approved test to moni-
tor the tumor response and recurrence of PC patients 
[35]. However, CA19-9 monitoring is unreliable as a sole 
marker because high levels are also possible in non-spe-
cific diseases such as liver damage or bile duct obstruc-
tion, diabetes, benign pancreatic disease and even in 
asymptomatic patients [36, 37]. Furthermore, some PC 
patients have normal CA19-9 levels [38, 39], and in this 
case their concentration does not allow detection of the 
tumor. Because of these shortcomings, several studies 
have focused on identifying potential blood-based car-
riers of CA19-9 as an alternative to the free circulating 
protein [40–44].
However, as explained above conventional technol-
ogy for exosome separation from whole blood based 
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on ultracentrifugation cycles [45–47] is limited by con-
tamination and exosome losses. As an alternative, a few 
studies have used microfluidic systems for PC exosomes 
isolation. Kanwar et al. [48] reported a platform function-
alized with anti-CD63 for on-chip isolation of exosomes 
from serum obtained from metastatic PC patients. They 
quantified the exosomes using a fluorescent carbocya-
nine dye that specifically binds to exosomes. In other 
study a multichannel nanofluidic system was designed 
to purify exosomes by an immunomagnetic recognition 
based on CD9, CD81 and EPCAM. The RNA cargo inside 
the exosomes was profiled, allowing identification of PC 
in a blind study [49]. Finally, Taller et al. [50], employed 
a microfluidic based strategy to analyse exosomal RNA 
based on surface acoustic wave exosome lysis and ion-
exchange nanomembrane sensor.
Here, we present a simple microdevice for exosome 
isolation, using it as a marker of PC in a proof of concept 
study. First, exosomes present in PBS, fetal bovine serum 
(FBS) and in whole blood were isolated by CD9-mediated 
magnetic capture. It must be remarked that exosome cap-
ture was done under continuous flow, with a residence 
time of 30  s. The exosomal identity was verified by the 
coexpression of a second exosomal protein CD63 quan-
tified by a CD63 ELISA test. Finally, exosomes from the 
whole blood of PC patients were captured and the exo-
somal CA19-9 protein levels were evaluated. The results 
show the potential of exosome separation and analysis as 
a marker of PC progression, with significant advantages 
compared to conventional monitoring methods.
Results and discussion
Microdevice design and operation
In general, mixture inside the capillary tubings operat-
ing in laminar flow regime conditions (Re < 2000) occurs 
mainly by diffusion. Under these conditions, the mix-
ing time is calculated by the Fick´s theory according to 
Eq.  (1). However, mixing is not very efficient and both 
axial and radial concentration profiles arise.
where dt is the tubing diameter and D is the diffusion 
coefficient.
To face the limited mixing and to promote fast kinetic 
events (antigen–antibody interaction) in low Re value, 
a coaxial jet mixer was considered (Fig.  1) [51]. On the 
one hand, according to previous studies, rapid mixing in 
coaxial mixers is achieved when the sheath flow is greater 
than the core flow [51]. Under proper fluid dynamic 
conditions (shear stress and linear velocity) high veloc-
ity streams come into contact with low velocity streams, 
(1)Mixing time = dt2/4D
producing eddy diffusion effects and rapid mixing [52]. 
On the other hand, the shear stress mismatch between 
low and fast velocity streams is able to produce turbu-
lence at the point of confluence, promoting entrainment 
of the low velocity fluid in the fast stream. According to 
previous results [51], the eddy diffusion effects are gener-
ally observed when the sheath flow is significantly faster 
than the core flow. In this case, a mixing time of 13 s and 
55 ms could be just achieved at a total flow rate of 120 μl/
min if the ratio core flow/sheath flow were ranged from 
1|1 to 1|11, respectively [51].
The operation principle of the coaxial mixer is 
described in detail in the experimental section and it is 
schematized in Fig. 1. A series of 12 (4 mm wide) NdFeB 
magnets were placed in contact with the outer wall of 
a PTFE duct with an outside diameter of 1.6  mm. The 
magnetic field intensity was high across the channel, but 
highest at the junctions between the magnets (Fig.  1d) 
and thus the  Fe3O4NPs contained in the flowing solu-
tion were retained preferentially at these locations. The 
operating procedure is schematised in Fig. 1a: First, the 
streams containing patient’s blood and antibody func-
tionalized nanoparticles  (Fe3O4–EDC-NHS-NPs-anti-
CD9) were introduced separately in a coaxial mixer and 
given 30 s to react before arriving to the magnetic sepa-
ration section. Then, the magnetic nanoparticle-exosome 
hybrids were trapped by the magnetic action of the per-
manent magnets and retained in the duct (Fig. 1c right). 
After capturing the exosome-NPs complexes  (Fe3O4–
EDC-NHS-NPs:anti-CD9-Exosomes), these were washed 
three times with PBS and finally the magnetic complexes 
were eluted after removing the magnetic field from the 
device. Once exosomes were purified from whole blood 
by the recognition of CD9, two different ELISAs were 
performed to the captured complexes (Fig. 1b): (i) ELISA 
1 to estimate the exosomal amount quantified indirectly 
by CD63 expression and (ii) ELISA 2 to evaluate the 
amount of CA19-9 protein present in the exosomal sam-
ple. The ELISA 1 was carried out to verify that the vesi-
cles captured were indeed exosomes (by the coexpression 
of CD9 and CD63). And then, once the capture of the 
exosomes in the microdevice was optimized, blood sam-
ples from pancreatic cancer were analyzed to evaluate the 
CA19-9 present specifically in their exosomes.
Figure 1c shows the experimental setup and the mag-
netic capture of the exosomes and nanoparticles (NPs) in 
the channel. A simulation of the magnetic gradient cre-
ated in the PTFE duct by the NdFeB magnets is depicted 
in Fig.  1d. The accumulation of magnetic exosome-NPs 
complexes observed in Fig.  1c is in agreement with the 
high intensity nodes depicted in Fig. 1d.
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Magnetic nanoparticle synthesis and antibody conjugation
Several works developed antibody-functionalized mag-
netic nanoparticles in order to develop immunocapture 
procedures for exosome isolation [21, 23, 48]. Antibody 
conjugation approaches include covalent coupling to NPs 
surface and non-covalent interactions, such us host–
guest interactions. In the last years, the employment of 
carboxyl-to-amine crosslinking has been extensively 
exploited due to its reproducibility and simplicity [53]. 
One of the main advantages of this procedure is that 
the antibody binding takes place in buffer and at room 
temperature.
As described in the experimental section, after the 
synthesis, the  Fe3O4NPs with a citrate coating were 
Fig. 1 Description of the microdevice. a Operation principle of the coaxial mixer. b ELISA analysis against CD63 and CA19‑9 performed after 
exosome capture from whole blood. c Left: Image of setup. Right: The pipe is lifted from the magnets showing the NPs captured at the junctions 
between the alternate polarization magnets. d Simulation of the magnetic gradient created between each pair of NdFeB magnets. Nanoparticle 
accumulation coincides with the high intensity nodes. The tubing is represented with the solid and dashed blue lines 
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magnetically separated from the reaction products and 
washed to remove unreacted precursors. The conjuga-
tion of the NPs with the antibody was carried out using 
a carbodiimide-succinimide covalent linker (see “Exper-
imental” section), to obtain a colloidal dispersion of 
 Fe3O4–EDC-NHS-NPs. In this reaction, the carboxylic 
group is first activated by N-ethyl-N’-(3-(dimethylamino)
propyl)carbodiimide (EDC) forming an ester, which rap-
idly reacts with N-hydroxysuccinimide (NHS) [54]. Fig-
ure  2a presents representative Transmission Electron 
Microscopy (TEM) images of both naked (where the term 
naked denotes magnetite NPs with only a citrate coating) 
and EDC-NHS grafted nanoparticles. The naked magnet-
ite NPs presented a polyhedral shape with very marked 
edges whereas the  Fe3O4–EDC-NHS-NPs showed an 
organic shell around them as well as less sharp edges 
compared with naked NPs (Fig.  2a). The mean diam-
eter of  Fe3O4NPs measured by TEM was 23.9 ± 5.7  nm 
whereas the mean diameter of the  Fe3O4–EDC-NHS-
NPs was 27.4 ± 4.6 (Fig. 2b). Fourier Transform Infrared 
(FT-IR) results (Fig.  2c) provide evidence of the func-
tionalization of the NPs with EDC-NHS. FT-IR spectra 
reveal that two characteristic bands at 1274  cm-1 (cor-
responding with C-N stretching) [55] and at 1650 cm−1 
(assigned to the C=O stretching) [56] appeared when the 
amide bond was formed between the carboxylic group 
of the citrate group of the  Fe3O4NPs and the amine from 
the EDC. The amount of EDC and NHS present in the 
 Fe3O4NPs could be quantified by Thermogravimetric 
Analysis (TGA). Figure 2d indicates that in the case of the 
naked NPs the amount of organic material was relatively 
low (around 5 wt. % of the NPs mass) corresponding 
with the presence of citrate groups on the NPs surface. 
On the contrary the TGA analysis of  Fe3O4–EDC-NHS-
NPs clearly revealed that the amount of organic mate-
rial significantly increased to almost 40 wt. % of the total 
nanoparticle mass, due to the presence of EDC and NHS 
functionalization. The magnetic properties of  Fe3O4–
EDC-NHS-NPs were measured at room temperature 
using vibrating-sample magnetometer (VSM). The hys-
teresis loop of the particles is shown in Additional file 1: 
Figure S1 and shows the expected superparamagnetic 
properties. This is in agreement with the magnetic prop-
erties of naked NPs [57]. Finally, at pH = 7 the zeta poten-
tial of the  Fe3O4NPs was − 29.4 ± 1.0 mV, similar to other 
citrate-coated iron oxide NPs [58], while for and  Fe3O4–
EDC-NHS-NPs it was + 16.14 ± 1.04 mV, a strong change 
that also corroborates functionalization.
The stability of the  Fe3O4–EDC-NHS-NPs coating 
was evaluated by X-Ray photoelectron spectroscopy 
(XPS) and Dynamic Light Scattering (DLS) for 30  days. 
XPS analysis (Fig. 3a) shows the evolution of NPs com-
position. For freshly synthesized nanoparticles the 
typical magnetite ratio (an abundance of 33 at. % and 66 
at. % of  Fe2+and  Fe3+) is observed. In the binding energy 
range of 700–740  eV, double peaks with binding ener-
gies of Fe 2p3/2 and Fe 2p1/2 at 710.6 and 724.8 eV can 
be observed, and it is also noteworthy the absence of 
the satellite peak around 719  eV, which is typical of the 
maghemite phase [59]. Nevertheless, as time increases, 
the amount of  Fe2+ gradually increasing while the  Fe3+ 
decreased. We attributed this iron reduction to the pres-
ence of the amide bond with the EDC-NHS, thus the 
nitrogen gradually displaces the  Fe3+ to  Fe2+ (Additional 
file 1: Figure S2A and B) [60]. In the Additional file the 
evolution of compositions for  Fe3O4NPs and  Fe3O4–
EDC-NHS-NPs for 30 days after synthesis is summarized 
(Additional file  1: Figure S2A). Figure  3b  indicates that 
although the surface charge of the  Fe3O4–EDC-NHS-
NPs was unchanged during 20 days (with a slight change 
around the value of + 15  mV, approximately), the zeta 
potential of the  Fe3O4NPs changed from negative to posi-
tive 7 days after their synthesis, which strongly suggests 
the loss of part of the citrate stabilization in the naked 
NPs. Zeta potential analysis of the NPs during 20  days 
evidenced the stability of the NPs functionalized with the 
EDC-NHS compared with the naked NPs. TEM images, 
FT-IR, TGA and Zeta potential results confirmed the 
functionalization of the magnetite nanoparticles with 
EDC-NHS for the subsequent antibody binding strategy 
[61, 62].
Antibody adherence to coated particles
The immobilization of the antibodies on the surface of 
NPs is a key step in the development of microdevices 
based on a magnetic capture. Since  Fe3O4–EDC-NHS-
NPs present good colloidal stability for at least 20 days, 
we used them for the covalent bonding of a commercial 
antibody (anti-CD9) to facilitate the application of this 
new vector in our microdevice. Nanodrop spectropho-
tometry measurements at 280  nm clearly indicated that 
when increasing the NPs:Ab w:w ratio, the amount of 
free CD9 in the supernatant decreased, demonstrating 
the efficient binding of the antibody to the  Fe3O4–EDC-
NHS-NPs. A high absorbance signal at 280  nm was 
detected for the lowest amount of nanoparticles (the 50:1 
sample) whereas, for a ratio of 200:1 the peak at 280 nm 
disappeared (Fig. 4a), indicating that the entire antibod-
ies were conjugated to the surface of the particles. Our 
results indicate that when we increased the amount of 
NPs, more antibodies were immobilized on the NPs 
surface. However, Saha et  al. [63] concluded that when 
covering a particle with antibodies not all the antibodies 
were able to capture the specific antigen. Moreover they 
evidenced that at a certain point, the number of active 
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antibodies decreases even more when the antibody cov-
erage increases due to steric hindrance.
The NPs-CD9 complexes were studied under Atomic 
Force Microscopy (AFM) (Fig.  4b). According to AFM 
images, lateral sizes of the  Fe3O4-NPs varied from 30 to 
50  nm. Also, observation of CD9 antibody alone on a 
mica surface showed a homogeneous monolayer of anti-
bodies coating the surface (Fig.  4b). This is in contrast 
with AFM observations on a mica surface coated with 
the antibody-functionalized nanoparticles, where dis-
tinct features can be observed. In particular, it is possi-
ble to observe the binding of the particles (central core in 
the nanoparticles of almost 7 nm in height, correspond-
ing with the magnetic core) to the CD9 antibody (arms 
surrounding the NPs of 4–5  nm height, similar to the 
CD9 alone). Thus, these results confirmed an increase 
on NPs diameter when they were covered with the CD9, 
(compared with naked NPs) evidencing the successful 
coupling of the particles with the antibody. Finally and 
before attempting to capture exosomes in the microde-
vice, the functionality of the  Fe3O4-EDC-NHS-NPs: anti-
CD9 complexes was tested in bulk. To do that, 40 μg of 
exosomes were put in contact with the functionalized 
 Fe3O4NPs surface covered with anti-CD9 at two different 
NPs:Ab ratios (100:1 and 50:1). Although it seems logical 
that increasing the NPs:Ab ratio and the time of incuba-
tion should lead to a higher exosomes capture, only slight 
and not statistically significant differences were found 
(Fig.  5a). Representative TEM images of the exosomes 
recognized by the  Fe3O4-EDC-NHS-NPs:anti-CD9 com-
plexes are showed in Fig. 5b. Captured exosomes appear 
bound to an organic shell (attributed to the EDC-NHS 
and anti-CD9 functionalization) and the  Fe3O4NPs. The 
characteristic double membrane of exosomes is clearly 
visualized in the captured exosomes (Fig.  5c). On the 
contrary, when using the magnetic NPs without the exo-
somal antibody, no exosomes were captured (results not 
shown).
Fig. 2 Characterization of  Fe3O4NPs before and after EDC‑NHS functionalization. a TEM images and size distribution histograms of the naked and 
the functionalized NPs. The EDC‑NHS shell is clearly visible around functionalized NPs. b Size distribution histograms of both nanoparticles. c FT‑IR 
analysis of the NPs solutions. d TGA results of the  Fe3O4NPs before and after EDC‑NHS functionalization
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Exosome capture in the microfluidic system
The capability of the microdevice was tested with 
exosomes in PBS and FBS. In TEM images of exosomes 
captured from PBS, FBS and whole blood (Fig.  6a) it 
is possible to observe the presence of the captured 
exosomes surrounded by the magnetic nanoparticles. 
Unavoidable, drying stages resulted in non-uniform 
nanoparticle deposition and the formation of nanopar-
ticle aggregates located in segregated patches. This phe-
nomena can be explained by the geometric constraints 
at the contact line of the evaporating droplet during sur-
face dewetting and the so called ‘coffee-ring’ effect [64]. 
However, the quality of TEM images is high enough to 
determine the presence of exosome-NPs complexes. In 
some of these complexes, the double lipid membrane 
of exosomes is clearly observed (Fig.  6b). Once the 
exosomes were captured in the microdevice by the forma-
tion of the  Fe3O4–EDC-NHS-NPs:anti-CD9 complexes, 
the amount of CD63 protein present was evaluated by an 
ELISA test (see experimental section) and the number of 
captured exosomes was obtained (Fig. 1b). In Fig. 6c the 
number of exosomes captured from PBS, FBS and whole 
blood is given. In all the samples, approximately 2 × 1010 
exosomes were captured when employing only 50 μg of 
 Fe3O4–EDC-NHS-NPs bound to anti-CD9 at 100:1 ratio 
in 500 μL. As a negative control, whole blood was injected 
thought the microdevice in presence of naked  Fe3O4–
EDC-NHS-NPs (without antibody functionalization). 
TEM images and antiCD63 ELISA results demonstrated 
the absence of exosomes after the capture, confirm-
ing the specific capture of exosomes by antibody-func-
tionalized nanoparticles. Finally, Nanoparticle Tracking 
Analysis (NTA) analysis of the captured exosomes was 
performed. Figure 6d  reveals a diameter of the particles 
and exosomes complexes of 130  nm. According to pre-
vious studies, exosomes have a diameter ranged from 30 
to 100  nm. Additional file  1: Figure S3A   shows a NTA 
analysis of control exosomes, revealing a mean diameter 
around 100  nm. On the contrary, the DLS of the parti-
cles alone indicate a mean hydrodynamic diameter of 
approximately 68 nm (Additional file 1: Figure S3B), also 
in concordance with the previous results considering the 
intrinsic agglomeration of the particles due to their mag-
netic properties.
Fig. 3 Stability of the magnetic NPs with time. a Analysis of Fe oxidation state by XPS in the naked MNPs. b Zeta potential evolution of naked and 
EDC‑NHS functionalized NPs
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Once the functionality of the method had been estab-
lished, the microfluidic device was employed to capture 
exosomes from whole blood. The possibility of using exo-
some monitoring as a diagnostic tool was explored by 
analysing the amount of CA19-9 present in exosomes 
captured from whole blood. Figure 7a shows that CA19-9 
levels in exosomes captured from whole blood were 
significantly higher in PC patients comparing with the 
levels of healthy donors. The sensitivity of exosome anal-
ysis is highlighted in the results obtained for patient 2, a 
false negative case  considering serum analysis (the free 
CA19-9 level in serum was normal, its exosomal CA19-9 
was significantly higher, giving a valuable diagnostic indi-
cation). The content of CA19-9 protein in the captured 
exosomes was used to identify PC patients from samples 
from healthy donors. The CA19-9 analysis in the cap-
tured exosomes was more sensitive than in serum, open-
ing a window of opportunity to avoid false negatives from 
the serum analysis, a common problem that limits the 
applicability of these biomarkers [65]. As Fig. 7b summa-
rizes, serum CA19-9 levels were not elevated (< 37 U/mL) 
[65] in one of the four evaluated patients, being a false 
negative. On the contrary, CA19-9 exosomal levels were 
overexpressed in the four PC subjects analysed. Although 
some aggregation of exosomes and nanoparticles was 
observed by TEM images (Fig. 6a), the specific and selec-
tive exosome capture was strong  enough (Fig.  6b) to 
detect the CA19-9 exosomal levels with a high sensitivity 
compared with free serum levels.
Exosomal CA19-9 levels were clearly enriched in all 
PC patients’ samples analysed compared to those from 
healthy donors. This is consistent with the results of 
Javeed et al. [66], who reported that EVs in PC patients 
were predominantly exosomes and their WB analysis 
revealed the presence of CA19-9 in all the PC patient-
derived exosome samples. They also showed that 
exosomes from control patients showed no CA19-9 lev-
els. The amount of exosomes in PC patients was signifi-
cantly higher compared with control group, suggesting 
that the difference is due to the production by pancre-
atic tumor cells [66]. However, their procedure involved 
a laborious series of ultracentrifugation and purifica-
tion steps, a process that compromises reproducibil-
ity. In contrast, the microdevice presented in this work 
allows to capture exosomes from blood easily even from 
whole blood samples, facilitating translation to the clinic. 
Although the proof of concept has been performed with 
PC patient samples, the microfluidic device could in prin-
ciple be used for the diagnosis of other pathologies just 
by changing the antibody of interest.
Fig. 4 Characterization of antibody coupling. a Nanodrop measurements of the NPs‑CD9 complexes at different NP/antibody weight ratios. b AFM 
images of the  Fe3O4NPs, of CD9 antibody and of  Fe3O4–EDC‑NHS‑NPs:anti‑CD9
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Conclusions
The isolation of exosomes and their subsequent analy-
sis is emerging as a promising technique in diagnostics 
and personalized medicine. However, current meth-
ods based on sequential centrifugation steps at high 
speeds require expensive equipment, highly trained 
personnel and are not amenable to automatic opera-
tion, which compromises reproducibility of analysis. 
In contrast, the device presented here allows for in-
flow capture and separation of exosomes from different 
fluids, including whole blood. It uses antibody-func-
tionalized magnetic nanoparticles that can be stored 
prior to use. Rather than a centrifugation/purification 
cascade, operation involves feeding the sample and 
the antibody-nanoparticle streams to a coaxial mixer, 
and collecting the captured exosomes downstream, 
after allowing for antibody recognition. The procedure 
is comparatively much faster and the device can be 
operated by personnel with basic skills. As a proof of 
concept, the microfluidic platform has been employed 
for the isolation of PC-derived exosomes from whole 
blood without the need of any pretreatment, and the 
results show a high sensitivity of PC-marker detection 
in the captured exosomes, compared to serum samples. 
The same operating principle could be adapted to the 
diagnosis of other diseases where characteristics pro-
teins are also enriched in patient exosomes.
Methods
Microdevice fabrication and operation
The inner and outer capillaries of the coaxial mixer were 
made of Polyether ether ketone-PEEK (hydrophilic) and 
Polytetrafluoroethylene-PTFE (hydrophobic), respec-
tively. The inner capillary diameter was 150 µm, whereas 
outer capillary diameter was 350 µm. The functionalized 
magnetic nanoparticles were injected (core flow) at a 
flow rate of 10 µL/min, whereas the exosome-containing 
fluid (sheath flow) was injected at a flow rate of 50 µL/
Fig. 5 Optimization of exosome capture. a Binding efficiency of exosomes by  Fe3O4–EDC‑NHS‑NPs at different time points at 50:1 and 100:1 
(NPs:Ab) weight ratios. b TEM images of exosomes captured by  Fe3O4–EDC‑NHS‑NPs:anti‑CD9. c High magnification images allow to visualize the 
double membrane of the exosomes in the complexes
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min (core flow: sheath flow ratio 1|5). The flow velocity 
ratio of the core and sheath streams was 5.5, a value high 
enough to promote a fast mixing of the functionalized 
magnetic nanoparticles in the exosome-containing fluid 
[67]. The inner capillary was coaxially placed  under an 
optical microscope to get an axisymmetric flow-focusing 
device where the magnetic nanoparticle phase is sur-
rounded symmetrically by the sheath phase. PTFE tubing 
was selected to avoid surface fouling by blood proteins 
and other biomolecules. The length of the PTFE tubing 
(inside diameter of 760  μm) was 10.5  cm (6.5  cm from 
the inner capillary to the first magnet), an overestimated 
length to assure a complete mixing [67] and antigen/
antibody interaction [68] before magnetic field interro-
gation. The coaxial capillary system was supported in a 
polymer housing fabricated by 3D-printing to avoid cap-
illaries misalignment and to favour fluid dynamic repro-
ducibility (Fig. 1c). The support for the device as well as 
the vial adapter were designed by Autodesk AutoCAD 
and were also 3D-printed. Two different syringe pumps 
(Harvard Apparatus PHD ULTRA™) were used to inject 
core and sheath streams. The coaxial mixer enables the 
purification of exosomes by inmmunomagnetically 
binding CD9 (exosomal protein surface marker) directly 
from unprocessed patients´ whole blood. Finally, a mag-
netic assembly with NdFeB permanent magnets with 
alternate polarization was used to achieve a high cap-
ture force thanks to the high magnetic field gradient cre-
ated between each magnet and the contiguous one. The 
simulation of the magnetic field distribution produced 
by the assembly of magnets has been performed with the 
FEMM freeware package (Fig. 1d).
NPs synthesis and characterization
The citrate functionalized  Fe3O4NPs were synthesized 
by scaling up a facile one-step method previously devel-
oped by Hui et al. [57] All the chemicals were provided 
by Sigma Aldrich. In brief, 2 mmol of  C6H5Na3O7·2H2O 
(citric acid, trisodium dehydrate), 8 mmol of NaOH, and 
0.4 mol of  NaNO3 were mixed in 18 mL of distilled  H2O. 
Then, the mixture was placed in a three-neck flask and 
heated to 100  °C. Separately, 2  mL of 2  M  FeSO4·4H2O 
solution was added into the mixture and it was kept at 
100 °C for 1 h, observing a colour change from pale white 
to dark brown, which corresponds with the formation 
Fig. 6 a TEM images from different locations of exosomes captured by the microfluidic device from PBS, FBS and whole blood. A negative control 
is also shown  (Fe3O4NPs‑EDC‑NHS without the antibody). The blue arrow indicates the membrane of the exosome surrounded by the particles. b 
Exosomes are in indicated with blue circles and arrows whereas the magnetic nanoparticles covering them are signaled with red arrows. c High 
Magnification images to visualize the double membrane of the exosomes in the complexes. ELISA CD63 results indicating the number of exosomes 
captured. d Particle size analysis of the captured exosomes in the microfluidic device by NTA
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of the  Fe3O4NPs. The final nanoparticle dispersion was 
cooled down to room temperature and the  Fe3O4NPs 
were washed with water by trapping them with a magnet 
three times. The brown precipitate was finally dispersed 
in water. Once the  Fe3O4NPs were synthesized, they were 
functionalized via covalent amide bonding by employ-
ing EDC and NHS in order to crosslink the carboxylic 
acid from the citrate group of the nanoparticles with 
the primary amines present in the FC region of the anti-
body (see scheme in Additional file  1). It is well known 
that the NHS ester is an intermediate product employed 
for the immobilization of biomolecules (peptides, anti-
bodies, etc.) containing free primary amino groups via 
amide linkage. First of all, the  Fe3O4NPs were mixed 
with the EDC (1:1, w:w) for 30  min at room tempera-
ture. In order to improve the efficiency of the reaction, 
the  Fe3O4-EDC-NPs were activated with NHS, forming 
an NHS ester which is significantly more stable than the 
intermediate generated between the carboxylic and the 
EDC groups. Both the EDC and the NHS functionaliza-
tion of the  Fe3O4NPs were performed at pH 5.5 in buffer 
MES. Finally, the subsequent  Fe3O4-EDC-NHS-NPs 
were washed three times with distilled water to stop the 
crosslinking reaction. Finally,  Fe3O4-EDC-NHS-NPs 
were conjugated to the primary amines present in the FC 
region of the antibodies at physiological pH (in Dulbec-
co’s Phosphate Buffered Saline (DPBS)).
The naked and the EDC-NHS functionalized  Fe3O4NPs 
were characterized by different physicochemical tech-
niques. First of all, they were thoroughly characterized 
by TEM operated at 200 kV with a LaB6 electron source 
fitted with a “SuperTwin®” objective lens. Particle solu-
tions were pipetted onto a TEM copper grid and then 
they were stained with 3% phosphotungstic acid (Sigma 
Aldrich, United States). The size distribution of the nan-
oparticles was obtained employing TEM images using 
ImageJ software (NIH-RSB) from at least 200 particles. 
TGA was performed in a temperature range between 
30 and 850  °C with a heating rate of 20  °C min−1 in  N2 
atmosphere to determine the citrate/Fe as well as the 
EDC-NHS/Fe ratios in the NPs (Mettler Toledo TGA/
STDA 851e). FT-IR spectra were recorded using a Bruker 
Vertex 70 FTIR spectrometer equipped with a DTGS 
detector, a horizontal attenuated-total-reflection acces-
sory with thermal control, and a diamond crystal (Golden 
Gate Heated Single Reflection Diamond ATR, Spec-
traTecknoroma). The FT-IR spectra both of  Fe3O4NPs 
and  Fe3O4-EDC-NHS-NPs were collected with 200 scans 
in the 400–4000 cm−1 spectral region at 4 cm−1 resolu-
tion. Magnetic properties at room temperature were 
measured by employing a vibrating sample magnetom-
eter (VSM Lake Shore 7410). Finally, the stability of both 
 Fe3O4NPs and  Fe3O4-EDC-NHS-NPs was evaluated dur-
ing 30  days by X-ray photoelectron spectroscopy analy-
sis (XPS) and dynamic light scattering DLS. The XPS 
analysis of the samples was performed with an Axis Ultra 
DLD (Kratos Tech.) apparatus to determine the relative 
abundance of  Fe2+ and  Fe3+. The samples were collected 
under glass coverslips and allowed to dry. The spec-
tra were excited by the monochromatized Al Kα source 
(1486.6  eV) run at 15  kV and 10  mA. For the individ-
ual peak regions, a pass energy of 20 eV was employed. 
Survey spectra were measured at 120  eV pass energy. 
The CasaXPS sofware was used to analyze the peaks. 
After the subtraction of the background, a weighted 
sum of Lorentzian and Gaussian components curve was 
employed. Furthermore, the zeta potential of both nano-
particle samples was measured at pH = 7 (Brookhaven 90 
plus and ZetaPALS software).
Antibody adherence to coated nanoparticles
Anti-CD9 antibody was purchased from Abcam. Several 
ratios  Fe3O4-EDC-NHS-NPs:anti-CD9 were investigated 
in order to optimize the labeling of the nanoparticles 
with the antibody. The Additional file 1: Figure S4 shows 
a scheme of the functionalization of the particles. The 
Fig. 7 Analysis CA19‑9 levels present in whole blood from PC 
patients. a ELISA CA19‑9 results indicating the overexpression of the 
proteins in the exosomes isolated from PC patients compared with 
healthy donors. b Serum CA19‑9 levels and exosomal CA19‑9 levels 
in PC patients. The PC patient II represents the false negative case, 
whose free serum CA19‑9 levels were in the normal range whereas 
the exosomal CA19‑9 levels were significantly increased
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amount of antibody was kept constant (1 μg) and the NPs 
mass was varied from 200 to 50 μg (200:1, 150:1, 100:1 and 
50:1; w:w) in a final volume of 10 μL (PBS). Thus, 1 μg of 
antibody was added to the activated NPs and the solutions 
were incubated for 4 h at room temperature with vortex-
ing every 15 to 30  min. To eliminate the unbound  anti-
CD9, the  Fe3O4-EDC-NHS-NPs:anti-CD9 were 
magnetically extracted and washed three times with PBS. 
To quantify the antibody binding ability, the supernatant 
of the  Fe3O4-EDC-NHS-NPs:anti-CD9 dispersion was 
measured with a UV–VIS spectrophotometer (Thermo 
Scientific Nanodrop 2000) by studying the absorption at 
280  nm. Then, the amount of anti-CD9 bounded to the 
NPs was indirectly estimated from the non-bounded anti-
body obtained in the supernatant. To estimate the protein 
concentration in the supernatant, the following formula 
was employed based on the absorbance of the aromatic 
rings of the amino acids of proteins (2) [69, 70]:
The  Fe3O4-EDC-NHS-NPs:anti-CD9 complexes were 
visualized following a Quantitative Nanoscale Mechani-
cal characterization (QNM peakforce mapping) by AFM 
in a Multimode 8 (Bruker Co., Billerica, MA, United 
States). The tip employed was a commercial tip (SNL 
model, type—C; Bruker). In order to analyze the anti-
CD9 antibody, a protocol previously reported by Ido 
et al. was followed [71]. Firstly, a 5 µL droplet of a 50 mM 
MgCl2 solution was deposited onto a freshly cleaved 
muscovite mica substrate. Then, a 5 µL droplet of the 
complexes dispersion was dropped on the substrate. Five 
minutes later, the substrate was gently rinsed five times 
with dH2O. AFM imaging was performed without drying 
the sample and the substrate. In order to guarantee that 
we were observing the  Fe3O4-EDC-NHS-NPs:anti-CD9 
complexes,  Fe3O4-NPs,  Fe3O4-EDC-NHS-NPs and CD9 
were also analyzed under the AFM.
Exosome capture
To verify the functionality of the nanoparticles cov-
ered with the antibody, the complexes (50:1 and 100:1, 
NPs:Ab w:w ratio) were incubated at room temperature 
with 40 µg of exosomes during 1 and 2 h. After that, the 
amount of captured exosomes was evaluated by indirectly 
measuring exosomes present in the supernatant. Thus 
exosomes recognized by the complexes were captured 
with a magnet and total protein amount of the exosomes 
present in the supernatant (non-captured exosomes) was 
quantified by Pierce BCA protein assay (Thermo Fisher 







= (1.55 · Abs280− 0.76 · Abs260)
PBS, serum and whole blood preparation
Exosomes present in PBS, serum and total whole blood 
were captured by the microdevice. In the case of PBS, the 
suspension was prepared by adding the previously puri-
fied exosomes  from cell cultures by ultracentrifugation 
cycles. Exosomes present in FBS were also isolated by 
the microdevice. Finally, all the assays involving human 
materials were approved by the Research Ethics Com-
mittee of the Community of Aragon (Comité de Ética de 
la Investigación de la Comunidad de Aragón -CEICA-): 
Extracción de exosomas de tumores y plasma de pacientes 
con diversos grados de malignidad, para el estudio de su 
composición y correlación clínica, PI18/198. Participants 
provided their written informed consent to partici-
pate in this study. Three control samples and seven PC 
patients were employed in this study. All the blood sam-
ples were obtained from recently diagnosed stage IV PC 
patients’ blood samples previously to the initiation of first 
line therapy and collected in vacutainer sodium citrate 
tubes in Hospital Universitario Miguel Servet, Zaragoza 
(Spain). Samples were stored during 2 h at 4 °C until use. 
500 μL of blood were employed for the exosomal capture 
in the microdevice.
Immunocapture and quantification of exosomes 
in the microdevice
An image of the experimental setup and the operating 
procedure together with a scheme of the operation prin-
ciple are shown in Fig. 1. To capture exosomes, 20 µg of 
 Fe3O4-EDC-NHS-NPs were conjugated to 200 ng of anti-
CD9 in 50 µL of PBS during 4 h. After that, the excess of 
non-bounded antibody was eliminated and the resulted 
 Fe3O4-EDC-NHS-NPs:anti-CD9 were dispersed in 500 
µL of PBS.
Then, the  Fe3O4-EDC-NHS-NPs:anti-CD9 and the exo-
some-containing sample were introduced into the micro-
fluidic chip. On the one hand, the magnetic nanoparticles 
conjugated to the antibody were fed at a flow rate of 10 
µL/min in the internal channel. On the other hand, the 
exosome sample was introduced at a flow rate of 50 µL/
min in the external channel. Firstly, exosomes were iso-
lated from three different fluid sources: PBS, FBS and 
whole blood. As negative control,  Fe3O4-EDC-NHS-NPs 
without being conjugated to CD9, were also passed 
through the microdevice in the presence of whole blood. 
The captured exosomes were finally characterized by 
TEM and ELISA. For TEM analysis, the captured sample 
was deposited onto a grid and was fixed with 3% phos-
photungstic acid (PTA). They were visualized following 
the previously described protocol. The number of cap-
tured exosomes was quantified by ExoELISA-ULTRA 
CD63 (System Biosciences, United States). The com-
plexes  Fe3O4-EDC-NHS-NPs:anti-CD9-exosomes 
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captured with the microdevice were deposited onto a 
96 well plate and were incubated with an anti-CD63 pri-
mary antibody for 1  h. Then a Horseradish Peroxidase 
(HRP) enzyme linked secondary antibody was employed 
for signal amplification. A colorimetric substrate of the 
HRP enzyme was added and the accumulation of the col-
oured product was measured by a microtiter plate reader 
at 450 nm absorbance. The accumulation of the coloured 
product was proportional to the amount of exosomes 
present in the sample. Finally, the concentration and the 
diameter of the captured exosomes were measured using 
Nanosight (Malvern Instruments, UK). With the aim of 
resuspending homogenously the complexes captured for 
Nanosight measurements, samples were diluted in PBS 
and sonicated in a bath after their capture in the mag-
netic device. Samples were measured at room tempera-
ture in triplicate for 60 s.
Exosome capture: ELISA CA19‑9 (blood from PC)
To quantify the exosomal CA19-9 amount present in 
exosomes of PC blood patients, whole blood (500 μL) 
was passed through the microdevice and exosomes were 
isolated as previously mentioned. Then, CA19-9 levels 
were analyzed by CA19-9 Human ELISA Kit (Thermo 
Fisher Scientific, United States) following manufacturer 
instructions. To guarantee that no free CA19-9 protein 
was captured and to avoid its interferences, the CA19-9 
was performed in the previously isolated fraction based 
on a sandwich capture with anti-CD9 and anti-CD63.
Statistical analysis
All the results expressed as the mean ± the standard devi-
ation were performed at least in triplicate. The statistical 
analysis of the data was carried out using the GraphPad 
Prism 7.04. Significance was determined by one-way 
analysis of variance (ANOVA): *P < 0.05.
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